NETTER-2, Lutetium Lu 177 for well-differentiated NET

Final OS from NETTER-1: lutetium-177-DOTATATE in patients with midgut NETsПодробнее

177Lu-DOTATATE in patients with well-differentiated, high-grade NETsПодробнее

Understanding Neuroendocrine TumorsПодробнее

Dr. Jonathan R. Strosberg on 177-Lu-Dotatate in Patients With Neuroendocrine TumorsПодробнее

Dr. Chauhan on the Role of 177Lu-Dotatate in NETsПодробнее

Dr. Strosberg on Retreatment With 177Lu-Dotatate in Advanced NETsПодробнее

NETTER-2: 177Lu-DOTATATE in gastroenteropancreatic NETsПодробнее

day2 ksnmmi 2013 - 19 Lu 177 Therapy in Neuroendocrine TumorПодробнее

June 2024: Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine StudyПодробнее

NETTER 1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu Dotatate EfficacПодробнее

NETTER-1: Radioactive Octreotide Effective in Metastatic Neuroendocrine TumorsПодробнее

Clinical Nuclear Medicine | PRRT, Lutathera and NETTER 1 trialПодробнее

NET discussion with Dr NavalkissoorПодробнее

Episode 24 - What to Know About Grade 3 Well-Differentiated NETsПодробнее

GI ASCO 2024 Highlights with Dr. Pamela Kunz – CheckMate 8HW, EMERALD-1, NETTER-2Подробнее

Dr. Philip on Adverse Events With Lutathera in NETsПодробнее

NETTER-1 update: 177Lu-DOTATATE in patients with midgut neuroendocrine tumorsПодробнее

Radioisotopic Targeting of NETs: Lutetium-177 Dotatate and What Does the Future Hold? by Dr.BushnellПодробнее

Recently Approved Drugs: Lutetium Lu 177 dotatate for treatment of GEP-NETsПодробнее